SCHEMBL1989282

SCHEMBL1989282

c1ccc(C2CCCCN2C2CCCCC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC18A3 Q16572 1/20 0.51
CHRNB2 P17787 1/20 0.50
CHRNB4 P30926 1/20 0.50
CHRNA3 P32297 1/20 0.50
CHRNA7 P36544 1/20 0.50
CHRNA4 P43681 1/20 0.50
HRH3 Q9Y5N1 1/20 0.50
NPSR1 Q6W5P4 1/20 0.46
OPRM1 P35372 4/20 0.45
OPRK1 P41145 4/20 0.45
OPRL1 P41146 4/20 0.45
OPRD1 P41143 3/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C19 P33261 1/20 0.45
PSEN1 P49768 1/20 0.43
PSEN2 P49810 1/20 0.43
APH1B Q8WW43 1/20 0.43
NCSTN Q92542 1/20 0.43
APH1A Q96BI3 1/20 0.43
PSENEN Q9NZ42 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18751629 1.00 SLC18A3 (0.51) SLC18A3CHRNB2CHRNB4CHRNA3CHRNA7
Hydrochloric Acid SCHEMBL28558595 0.98 SLC18A3 (0.50) SLC18A3CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL9153287 0.98 CHRNB2 (0.52) SLC18A3CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL18751630 0.96 CHRNB2 (0.50) SLC18A3CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL9153176 0.96 CHRNB2 (0.55) SLC18A3CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL10770079 0.96 CHRNB2 (0.50) SLC18A3CHRNB2CHRNB4CHRNA3CHRNA7
Hydrochloric Acid SCHEMBL10764868 0.95 HRH3 (0.49) SLC18A3CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL17114372 0.94 CHRNB2 (0.52) SLC18A3CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL13660506 0.93 HRH3 (0.57) SLC18A3CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL13660513 0.91 CHRNB2 (0.56) SLC18A3CHRNB2CHRNB4CHRNA3CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250224340-A1 Colorimetric Detection of Organic Amines Using Metal-Organic Frameworks THE JOHNS HOPKINS UNIVERSITY 2025-07-10 US claimed
CN-114137233-A Quantitative detection test strip, kit and method for phencyclidine 佛山墨赛生物技术有限公司 2022-03-04 CN claimed
WO-2011091418-A1 SCREENING METHOD FOR ADVERSE SIDE EFFECTS OF A THERAPEUTIC PHARMACEUTICAL DRUG NORTHEASTERN UNIVERSITY (US) 2011-07-28 WO claimed
EP-4362926-A1 MODIFIED RELEASE FORMULATIONS OF METHADONE AND ITS ISOMERS, ESMETHADONE AND LEVOMETHADONE AND DERIVATIVES Manfredi, Paolo L. (US) 2024-05-08 EP disclosed
CN-117999071-A Modified release formulations of methadone and its isomers, esomeprazole and levomethadone and derivatives 保罗·L·曼佛雷蒂 2024-05-07 CN disclosed
US-20240122878-A1 MODIFIED RELEASE FORMULATIONS OF METHADONE AND ITS ISOMERS, ESMETHADONE AND LEVOMETHADONE AND DERIVATIVES MANFREDI PAOLO L (US) 2024-04-18 US disclosed
US-20240115203-A1 SWEAT PATCH WITH IMPROVED ADHESION AND ANTI-TAMPERING FEATURE(S) Smart Sales, LLC dba Smartox 2024-04-11 US disclosed
US-11754560-B2 Apparatus for collecting and detecting an analyte in a fluid sample Healgen Scientific Limited (US) 2023-09-12 US disclosed
US-11730744-B2 Methods of reducing risk of preterm birth COVIS PHARMA GMBH (CH) 2023-08-22 US disclosed
WO-2023278400-A1 MODIFIED RELEASE FORMULATIONS OF METHADONE AND ITS ISOMERS, ESMETHADONE AND LEVOMETHADONE AND DERIVATIVES UNIVERSITY OF PADOVA (IT) 2023-01-05 WO disclosed
US-11304962-B2 Methods of reducing risk of preterm birth COVIS PHARMA GMBH (CH) 2022-04-19 US disclosed
US-20080269202-A1 Novel 2,3-benzodiazepine derivatives and their use as antipsychotic agents TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2008-10-30 US disclosed
WO-2008124075-A1 NOVEL 2,3-BENZODIAZEPINE DERIVATIVES AND THEIR USE AS ANTIPSYCHOTIC AGENTS TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2008-10-16 WO disclosed
CN-101052393-A Novel polymorphs of azabicyclohexane DOV PHARMACEUTICAL INC (US) 2007-10-10 CN disclosed
EP-1786417-A2 NOVEL POLYMORPHS OF AZABICYCLOHEXANE DOV Pharmaceutical, Inc. (US) 2007-05-23 EP disclosed
US-20070043100-A1 Novel polymorphs of azabicyclohexane ETHISMOS RESEARCH, INC. 2007-02-22 US disclosed
WO-2006023659-A2 NOVEL POLYMORPHS OF AZABICYCLOHEXANE DOV PHARMACEUTICAL, INC. (US) 2006-03-02 WO disclosed
WO-1989001160-A1 NEW BIFUNCTIONAL PHOTOEXCITABLE REAGENTS, THEIR PREPARATION AND USE, IN PARTICULAR FOR PHOTOAFFINITY LABELLING CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) 1989-02-09 WO disclosed
US-4118393-A Phenyl azabicyclohexanones AMERICAN CYANAMID COMPANY (US) 1978-10-03 US disclosed
US-4118417-A Process for resolving cis-1-substituted phenyl-1,2-cyclopropanedicarboxylic acids AMERICAN CYANAMID COMPANY (US) 1978-10-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269202-A1 Novel 2,3-benzodiazepine derivatives and their use as antipsychotic agents GABRA3, GABRB3, GABRA4 SLC18A3 189/4885CHRNB2 78/4885CHRNB4 88/4885
US-20070043100-A1 Novel polymorphs of azabicyclohexane CYP3A43, CYP2D6, CYP26B1 SLC18A3 2878/4885CHRNB2 2852/4885CHRNB4 2697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.